Polymyositis
Diseases characterized by inflammation involving multiple muscles. This may occur as an acute or chronic condition associated with medication toxicity (DRUG TOXICITY); CONNECTIVE TISSUE DISEASES; infections; malignant NEOPLASMS; and other disorders. The term polymyositis is frequently used to refer to a specific clinical entity characterized by subacute or slowly progressing symmetrical weakness primarily affecting the proximal limb and trunk muscles. The illness may occur at any age, but is most frequent in the fourth to sixth decade of life. Weakness of pharyngeal and laryngeal muscles, interstitial lung disease, and inflammation of the myocardium may also occur. Muscle biopsy reveals widespread destruction of segments of muscle fibers and an inflammatory cellular response. (Adams et al., Principles of Neurology, 6th ed, pp1404-9)
Subtype terms (1)
More specific conditions that are subtypes of Polymyositis in the MeSH hierarchy.
- Dermatomyositis
73 drugs (43 approved, 30 experimental)
Drugs by status
Approved for this indication (1)
Phase 3 trials (11)
Phase 2 trials (15)
Phase 1 trials (3)
Other trials (1)
Organizations
Organization Involved with Phase 3 Indications (10)
Organization Involved with Phase 2 Indications (11)
- Genentech
- Biogen
- Novartis
- Mallinckrodt
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- National Institute of Environmental Health Sciences (NIEHS)
- National Institute of Neurological Disorders and Stroke (NINDS)
- University of Pittsburgh
- University of London
- Mayo Clinic
- Kezar Life Sciences, Inc.
Organization Involved with Other Experimental Indications (1)